Revenue and margin growth are primarily driven by the successful launch and increasing sales of Emrosi, improvements in gross margin, expansion of payer coverage, and disciplined cost management despite ongoing competitive pressure on legacy products.
Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)
By Press Room
